Melanoma Dispatch
2.6K views | +0 today
Follow
News for Patients and Physicians
Curated by Cancer Commons
Your new post is loading...
Your new post is loading...
Scooped by Cancer Commons
Scoop.it!

OncoSec Medical Presents Positive Phase 2 Interim Data Evaluating ImmunoPulse in Melanoma

"OncoSec Medical Inc. (OTCQB: ONCS), a company developing its ImmunoPulse DNA-based intratumoral cancer immunotherapy, announced interim data from its Phase 2 melanoma study at the American Society of Clinical Oncology’s (ASCO) 50th Annual Meeting in Chicago. The abstract, titled “Systemic anti-tumor effect and clinical response in a Phase 2 trial of intratumoral electroporation of plasmid interleukin-12 in patients with advanced melanoma” (ASCO Abstract #9025), was presented by Adil Daud, M.D., OncoSec’s Chief Clinical Strategist and Principal Investigator of the Phase 2 melanoma study, and selected for discussion during a poster highlights session for melanoma/skin cancers led by Axel Hauschild, M.D., Ph.D."


Editor's note: This article describes a promising immunotherapy treatment that boosts a patient's own immune system to fight melanoma. 

Cancer Commons's insight:

Yahoo! Finance  |  Jun 2, 2014

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

New Immunotherapy May Turn IL-12 On and Off in Melanomas

New Immunotherapy May Turn IL-12 On and Off in Melanomas | Melanoma Dispatch | Scoop.it

Doctors may someday be able to adjust interleukin-12 (IL-12) levels in melanomas at will, according to results of an ongoing clinical trial presented at Melanoma Bridge 2013 Conference in Naples, Italy. IL-12 is an immune system protein that can shrink melanomas, but also has nasty side effects. The experimental immunotherapy entails injecting tumors with a virus that does not cause diseas, and that has been engineered to produce the IL-12 when people take a drug called veledimex. In the phase I/II trial of 21 people with melanomas that had been injected with this engineered virus, IL-12 production turned on when they took veledimex and turned off when they stopped. Depending on the dose, veledimex increased IL-12 production by 1,000 to 100,000 times.

Cancer Commons's insight:

ZIOPHARM Oncology, Inc. │Dec 7, 2013

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

IL-12 Therapy May Shrink Melanomas Not Directly Treated

IL-12 Therapy May Shrink Melanomas Not Directly Treated | Melanoma Dispatch | Scoop.it

An experimental immunotherapy that delivers interleukin-12 (IL-12) directly into a melanoma tumor may also shrink tumors elsewhere in the body. Called ImmunoPulse, the treatment entails injecting a tumor with interleukin-12 DNA and delivering electric shocks to make the tumor cells absorb this DNA. These cells then produce IL-12, boosting the immune response against the tumor. In an ongoing phase II trial of 21 people with melanomas that were treated with ImmunoPulse, tumors shrank in 8 of them (38%) and disappeared for at least 6months in 2 more of them. Moreover, untreated tumors also shrank in about 60%. The possibility of body-wide effects is encouraging because, in contrast to systemic IL-12 therapy, ImmunoPulse treatments have yet to cause serious side effects.

Cancer Commons's insight:

OncoSec Medical Inc. │ Dec 16, 2013

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

Virus Engineered to Make Interleukin Shrinks Melanomas in Early Trial

Virus Engineered to Make Interleukin Shrinks Melanomas in Early Trial | Melanoma Dispatch | Scoop.it

An experimental treatment shrinks melanomas by pumping them full of interleukin-12, a protein that boosts the body's immune response against cancer. Developed by ZIOPHARM Oncology, the treatment has two steps: 1) injecting tumors with Ad-RTS-IL-12, a virus that has been engineered to make interleukin, and 2) controlling how much interleukin is made with a drug called INXN‑1001. A phase I clinical trial showed that this treatment increases white blood cells near melanomas and makes tumors flatter and smaller. These findings were presented at the American Society for Clinical Oncology's 2013 meeting. A phase II trial of this immunotherapy is underway in up to 15 patients.

Cancer Commons's insight:

Global Newswire│Jun 1, 2013

more...
No comment yet.